Showing 781-790 of 1201 results for "".
- Cutera Launches Heroes Among Us Programhttps://modernaesthetics.com/news/cutera-launches-heroes-among-us-program/2472851/Cutera is launching its new “Heroes Among Us” program to showcase patients who’ve been positively affected by Cutera technologies. The new program was launched at the Cutera University Clinical
- Merz: Cellfina for Cellulite Cleared for 5 Years of Benefithttps://modernaesthetics.com/news/merz-cellfina-for-cellulite-cleared-for-5-years-of-benefit/2472836/The FDA has cleared a new indication statement for Cellfina that shows the benefits of treatment last for five years, an increase from the previous three-year indication. Cellfina from Merz demonstrated five-year improvement in the appearance of cellulite on the buttocks and thighs of adult femal
- Physician Dispensing Exclusive: Altreno in 20g Tubehttps://modernaesthetics.com/news/physician-dispensing-exclusive-altreno-in-20g-tube/2472831/Altreno (tretinoin) Lotion, 0.05%, is now available exclusively for physician dispensing in a 20-gram size. Launched last year, Altreno Lotion from Ortho Dermatologics is the first and only tretinoin available in a lotion for the treatment of acne that has been shown to be effectiv
- British Plastic Surgeons to Vote on Brazilian Butt Lift Banhttps://modernaesthetics.com/news/british-plastic-surgeons-to-vote-on-brazilian-butt-lift-ban/2472830/It’s been called the deadliest cosmetic surgery procedure in the world, and now the British Association of Aesthetic Plastic Surgeons (BAAPS) is launching a formal safety review of Brazilian butt lifts that will culminate with a vote on whether to ban fat grafting buttock augmentation.
- Sciton Introduces JOULE X at ASLMShttps://modernaesthetics.com/news/sciton-introduces-joule-x-at-aslms/2471929/Sciton Inc. unveiled JOULE X and other new offerings at the annual American Society for Laser Medicine and Surgery Meeting in Denver, Colorado. An upgrade to the JOULE platform, JOULE X is the company’s latest multi-device platform. It works
- BTL News: New Small Emsculpt Applicator Targets Arms, Thighs, Calveshttps://modernaesthetics.com/news/btl-news-new-small-emsculpt-applicator-targets-arms-thighs-calves/2471930/BTL is rolling out a small Emsculpt applicator to treat arms, thighs and calves at the annual meeting of the American Society for Laser Medicine and Surgery in Denver. Until now, there were only protocols for the abdominals and buttocks. In addition to launching the small applicat
- Vic A Narurkar, MD: Remembering a Legendhttps://modernaesthetics.com/news/vic-a-narurkar-md-remembering-a-legend/2471955/The dermatology community lost a true rock star with the sudden passing of Vic A Narurkar MD, FAAD in late January. Loved by so many, Dr. Narurkar was the Founder of the Bay Area Laser Institute in San Francisco and a past president of the American Society of Cosmetic Derma
- Christie Brinkley Partners with Merz to Launch New “Milestones of Me” Campaignhttps://modernaesthetics.com/news/christie-brinkley-partners-with-merz-to-launch-new-milestones-of-me-campaign/2471958/Merz Americas is partnering with supermodel, actress, and entrepreneur, Christie Brinkley, to launch a new campaign, “Milestones of Me,” which encourages women to celebrate the moments, big or small, that have made them who they are today. The campaign kicks off in honor of Christie&r
- Merz Americas Rolls Out New Xeomin ‘Later Haters' Campaignhttps://modernaesthetics.com/news/merz-americas-rolls-out-new-xeomin-later-haters-campaign/2471983/Merz Americas is launching a new advertising campaign for Xeomin (incobotulinumtoxinA) called “Later Haters,” which urges women to “X out” judgment, stop apologizing for caring about how they look and put an end to feeling
- Revance Shares Positive Efficacy and Duration Data for RT002https://modernaesthetics.com/news/revance-share-positive-efficacy-and-duration-data-for-rt002/2471986/Revance Therapeutics, Inc.'s long-acting neuromodulator daxibotulinumtoxinA for Injection (RT002) with its proprietary stabilizing excipient peptide technology delivered positive top-line results in alleviating moderate to severe glabellar lines in the SAKURA 3 Phase 3 open-label, long-term s